|
102 Companies |
|
136 Products |
|
136 Products |
|
123 Mechanisms of Action |
|
5 Trials |
|
1111 News |
|
| «12...4567891011121314...1617» |
- ||| Enrollment open, Metastases: Non-Interventional Study PREVENT (clinicaltrials.gov) - Jul 21, 2014
P=N/A, N=200, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting
- Enrollment change, Trial termination, Trial primary completion date: Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects. (clinicaltrials.gov) - Jul 18, 2014
P2, N=17, Terminated, Sponsor: Copenhagen University Hospital at Herlev
Not yet recruiting --> Recruiting N=28 --> 17 | Recruiting --> Terminated | Trial primary completion date: Aug 2010 --> Nov 2010; Primary endpoint measure not suitable for evaluation
- || New P3 trial: Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance (clinicaltrials.gov) - Jul 15, 2014
P3, N=460, Not yet recruiting, Sponsor: University of Toronto
- Clinical: Comparison of Tension Free Primary Closure, Karydaks and Limberg Flap Methods (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=150, Completed, Sponsor: Konya Training and Research Hospital
- budesonide inhalation suspension / Generic mfg.
New P1 trial: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Jul 12, 2014
P1, N=20, Recruiting, Sponsor: Vanderbilt University
- ||| lansoprazole / Generic mfg.
Trial completion: Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=3502, Completed, Sponsor: Takeda
N=28 --> 17 | Recruiting --> Terminated | Trial primary completion date: Aug 2010 --> Nov 2010; Primary endpoint measure not suitable for evaluation Active, not recruiting --> Completed
- ||||| asenapine / Generic mfg.
Enrollment closed: Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384) (clinicaltrials.gov) - Jul 4, 2014
P3b, N=550, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Trial primary completion date: iTEPsein: ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA (clinicaltrials.gov) - Jul 1, 2014
P1/2, N=60, Recruiting, Sponsor: Nantes University Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2016
- Proellex (telapristone) / AbbVie
Enrollment change: Safety and Efficacy of 25 and 50 mg Doses of Proellex (clinicaltrials.gov) - Jun 27, 2014
P3, N=0, Withdrawn, Sponsor: Repros Therapeutics Inc.
Trial primary completion date: Dec 2014 --> Dec 2016 N=400 --> 0
- MRI: Magnetic Resonance Imaging of Mesh Position After Ventral Hernia Repair (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=15, Recruiting, Sponsor: Algemeen Ziekenhuis Maria Middelares
- | New P1/2 trial: Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma (clinicaltrials.gov) - Jun 27, 2014
P1/2, N=100, Recruiting, Sponsor: Daniel Lee, MD
- Clinical: Clinical Benefits of Additional Complex Fractionated Atrial Electrogram Targeted Catheter Ablation for Longstanding Persistent Atrial Fibrillation (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=220, Not yet recruiting, Sponsor: Yonsei University
- ||||| Trial initiation date: A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. (clinicaltrials.gov) - Jun 22, 2014
P3, N=414, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=400 --> 0 Initiation date: Oct 2005 --> Feb 2005
- |||| Civacir (hepatitis C immune globulin) / ADMA Biologics, Kedrion
Trial primary completion date: Civacir (clinicaltrials.gov) - Jun 19, 2014
P3, N=90, Recruiting, Sponsor: Biotest Pharmaceuticals Corporation
Initiation date: Oct 2005 --> Feb 2005 Trial primary completion date: Dec 2014 --> Jul 2015
- Avastin (bevacizumab) / Roche
Trial primary completion date: Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 18, 2014
P2, N=5, Terminated, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Mar 2011 --> Dec 2011
- Avastin (bevacizumab) / Roche
Trial termination: Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 18, 2014
P2, N=5, Terminated, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Mar 2011 --> Dec 2011 Suspended --> Terminated; Recruitment has been terminated prematurely because of poor enrollment.
- Avastin (bevacizumab) / Roche
Enrollment change, Trial termination, Trial primary completion date: Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 18, 2014
P2, N=5, Terminated, Sponsor: Beth Israel Deaconess Medical Center
Suspended --> Terminated; Recruitment has been terminated prematurely because of poor enrollment. N=32 --> 5 | Suspended --> Terminated | Trial primary completion date: Mar 2011 --> Dec 2011; Recruitment has been terminated prematurely because of poor enrollment.
- ||||||| NN1213 / Novo Nordisk
Trial completion: A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. (clinicaltrials.gov) - Jun 18, 2014
P3, N=414, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=32 --> 5 | Suspended --> Terminated | Trial primary completion date: Mar 2011 --> Dec 2011; Recruitment has been terminated prematurely because of poor enrollment. Active, not recruiting --> Completed
- Trial primary completion date, Metastases: Dose Escalating Study for Amphinex-based PCI of Bleomycin. (clinicaltrials.gov) - Jun 17, 2014
P1, N=3, Completed, Sponsor: PCI Biotech AS
Active, not recruiting --> Completed Trial primary completion date: Jul 2013 --> Oct 2012
- Trial completion, Trial primary completion date, Metastases: Dose Escalating Study for Amphinex-based PCI of Bleomycin. (clinicaltrials.gov) - Jun 17, 2014
P1, N=3, Completed, Sponsor: PCI Biotech AS
Trial primary completion date: Jul 2013 --> Oct 2012 Recruiting --> Completed | Trial primary completion date: Jul 2013 --> Oct 2012
- Daklinza (daclatasvir) / BMS
Combination therapy: A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=0, Available, Sponsor: Bristol-Myers Squibb
- ||||| Dexilant (dexlansoprazole) / Takeda
New P4 trial: Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation (clinicaltrials.gov) - Jun 13, 2014
P4, N=150, Not yet recruiting, Sponsor: Takeda
- Trial primary completion date: PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma (clinicaltrials.gov) - Jun 3, 2014
P2, N=500, Recruiting, Sponsor: Arizona Molecular Imaging Center
Recruiting --> Completed | Trial primary completion date: Jul 2013 --> Oct 2012 Trial primary completion date: Apr 2014 --> Apr 2015
- || Trial primary completion date, Metastases: Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients. (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Apr 2014 --> Apr 2015 Trial primary completion date: Mar 2014 --> Jul 2014
- ||| Metastases: Non-Interventional Study PREVENT (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=200, Not yet recruiting, Sponsor: AstraZeneca
- Clinical: Impact of Continuous Defocused CO2 Laser Vaporisation on the Histological Malignant Transformation of Erosive Oral Lichen Planus in Patients (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=263, Completed, Sponsor: Technische Universität München
- |||| NeuVax (nelipepimut-S) / Dr. Reddy's
Trial primary completion date: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - May 27, 2014
P3, N=700, Recruiting, Sponsor: Galena Biopharma, Inc.
Trial primary completion date: Mar 2014 --> Jul 2014 Trial primary completion date: May 2015 --> Jun 2017
- ||| NeuVax (nelipepimut-S) / Dr. Reddy's
Trial completion date: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - May 27, 2014
P3, N=700, Recruiting, Sponsor: Galena Biopharma, Inc.
Trial primary completion date: May 2015 --> Jun 2017 Trial completion date: May 2022 --> Jun 2024
- Tumor cell: Circulating Tumor Cells in Operative Blood (clinicaltrials.gov) - May 26, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: University of Florida
- Trial primary completion date: PRET: Patients Prone to Recurrence After Endovascular Treatment (clinicaltrials.gov) - May 26, 2014
P4, N=500, Active, not recruiting, Sponsor: Centre hospitalier de l'Universit
Trial completion date: May 2022 --> Jun 2024 Trial primary completion date: Jun 2014 --> Feb 2015
- Trial completion date: PRET: Patients Prone to Recurrence After Endovascular Treatment (clinicaltrials.gov) - May 26, 2014
P4, N=500, Active, not recruiting, Sponsor: Centre hospitalier de l'Universit
Trial primary completion date: Jun 2014 --> Feb 2015 Trial completion date: Jun 2014 --> Jan 2016
- ||| Trial completion: EURO KLEAR: A Post Market Study Evaluating the Safety, Device Perfomance and Possible Emergent Risks of Celotres in Preventing Recurrence in Keloid Lesions Treated Adjunctive to Surgical Excision (clinicaltrials.gov) - May 23, 2014
P=N/A, N=51, Completed, Sponsor: Halscion, Inc.
Trial completion date: Jun 2014 --> Jan 2016 Active, not recruiting --> Completed
- || Trial primary completion date: Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers (clinicaltrials.gov) - May 20, 2014
P2, N=70, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Feb 2015
- cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores (clinicaltrials.gov) - May 20, 2014
P2, N=40, Recruiting, Sponsor: Emory University
Trial primary completion date: Sep 2014 --> Feb 2015 Trial primary completion date: Oct 2014 --> Feb 2015
- cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Trial completion date: Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores (clinicaltrials.gov) - May 20, 2014
P2, N=40, Recruiting, Sponsor: Emory University
Trial primary completion date: Oct 2014 --> Feb 2015 Trial completion date: Oct 2014 --> Feb 2015
- Enrollment closed, HEOR: Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer (clinicaltrials.gov) - May 19, 2014
P=N/A, N=48, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial completion date: Oct 2014 --> Feb 2015 Recruiting --> Active, not recruiting
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Trial primary completion date: Herbal Therapy for Treatment of Recurrent Prostate Cancer (clinicaltrials.gov) - May 18, 2014
P2, N=45, Active, not recruiting, Sponsor: University of Southern California
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2014 --> Jul 2015
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Trial completion date: Herbal Therapy for Treatment of Recurrent Prostate Cancer (clinicaltrials.gov) - May 18, 2014
P2, N=45, Active, not recruiting, Sponsor: University of Southern California
Trial primary completion date: Jul 2014 --> Jul 2015 Trial completion date: Jul 2015 --> Jul 2016
- Trial primary completion date, Surgery, Biopsy: Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (clinicaltrials.gov) - May 15, 2014
P2, N=2, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Jul 2015 --> Jul 2016 Trial primary completion date: May 2013 --> Sep 2013
- ||| EXC 001 / Pfizer
Enrollment closed, Surgery: Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery (clinicaltrials.gov) - May 13, 2014
P2, N=100, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: May 2013 --> Sep 2013 Recruiting --> Active, not recruiting
- |||| imatinib / Generic mfg.
Trial completion, Stroma: Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) - May 13, 2014
P4, N=132, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial primary completion date: hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP) (clinicaltrials.gov) - May 12, 2014
P3, N=1095, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Recruiting --> Completed Trial primary completion date: Feb 2014 --> Jul 2014
- Trial primary completion date: J-STARS Echot: Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo) (clinicaltrials.gov) - May 12, 2014
P3, N=854, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Trial primary completion date: Feb 2014 --> Jul 2014 Trial primary completion date: Feb 2014 --> Jul 2014
- pravastatin / Generic mfg.
Trial primary completion date: Japan Statin Treatment Against Recurrent Stroke (J-STARS) (clinicaltrials.gov) - May 12, 2014
P3, N=1578, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Trial primary completion date: Feb 2014 --> Jul 2014 Trial primary completion date: Feb 2014 --> Jul 2014
- Trial completion date: hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP) (clinicaltrials.gov) - May 12, 2014
P3, N=1095, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Trial primary completion date: Feb 2014 --> Jul 2014 Trial completion date: Feb 2014 --> Jul 2014
- Trial completion date: J-STARS Echot: Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo) (clinicaltrials.gov) - May 12, 2014
P3, N=854, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Trial completion date: Feb 2014 --> Jul 2014 Trial completion date: Feb 2014 --> Jul 2014
- pravastatin / Generic mfg.
Trial completion date: Japan Statin Treatment Against Recurrent Stroke (J-STARS) (clinicaltrials.gov) - May 12, 2014
P3, N=1578, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Trial completion date: Feb 2014 --> Jul 2014 Trial completion date: Feb 2014 --> Jul 2014
- Biomarker: The Evaluation for Prognostic Factors After Catheter Ablation of Atrial Fibrillation: Cohort Study (clinicaltrials.gov) - May 12, 2014
P=N/A, N=3100, Not yet recruiting, Sponsor: Yonsei University
- |||| asenapine / Generic mfg.
Trial primary completion date: Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384) (clinicaltrials.gov) - May 7, 2014
P3b, N=550, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Feb 2014 --> Jul 2014 Trial primary completion date: Apr 2015 --> Jun 2015
- ||| asenapine / Generic mfg.
Trial completion date: Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384) (clinicaltrials.gov) - May 7, 2014
P3b, N=550, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Apr 2015 --> Jun 2015 Trial completion date: Apr 2015 --> Jun 2015